Inspire Medical Systems (NYSE:INSP) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Inspire Medical Systems (NYSE:INSP) announced its quarterly earnings data on Tuesday. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.09, Briefing.com reports. Inspire Medical Systems had a negative net margin of 40.36% and a negative return on equity of 18.32%. The firm had revenue of $20.86 million during the quarter, compared to analysts’ expectations of $19.15 million. During the same quarter last year, the business earned ($0.22) earnings per share. The business’s revenue for the quarter was up 59.8% compared to the same quarter last year.

Inspire Medical Systems stock opened at $61.10 on Friday. Inspire Medical Systems has a 1 year low of $35.43 and a 1 year high of $71.71. The firm has a 50 day moving average price of $58.93 and a 200 day moving average price of $60.07. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -40.74 and a beta of 1.22. The company has a debt-to-equity ratio of 0.16, a quick ratio of 20.05 and a current ratio of 20.46.

In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $58.61, for a total transaction of $1,465,250.00. Also, insider Randy Ban sold 19,300 shares of the business’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $59.16, for a total transaction of $1,141,788.00. Over the last 90 days, insiders sold 191,790 shares of company stock valued at $12,433,812. 12.10% of the stock is owned by insiders.

Several analysts recently commented on the stock. ValuEngine cut shares of Inspire Medical Systems from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Berenberg Bank upgraded shares of Inspire Medical Systems from a “sell” rating to a “hold” rating and raised their price objective for the company from $46.00 to $51.00 in a research note on Wednesday. Zacks Investment Research downgraded shares of Inspire Medical Systems from a “buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, Dougherty & Co set a $78.00 target price on shares of Inspire Medical Systems and gave the company a “buy” rating in a report on Friday, September 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $67.25.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Read More: What Does a Sell-Side Analyst Rating Mean?

Earnings History for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.